From DCAT Value Chain Insights (VCI)
Gilead Sciences, Inc. reports that Philippe C. Bishop, MD, will join the company as senior vice president, hematology and oncology therapeutics. In this position, Dr. Bishop will report to John McHutchison, MD, executive vice president, clinical research and will have responsibility for Gilead’s programs in oncology. Dr. Bishop will also join Gilead’s Executive Committee.
Dr. Bishop joins Gilead from Genentech, where he has served as vice president, product development, oncology since 2007. At Genentech, he was responsible for the development of Avastin, contributed to many of the company’s oncology pipeline therapeutics and was a member of the Roche/Genentech joint leadership team. Prior to joining Genentech, Dr. Bishop led efforts to develop cancer therapies at Johnson & Johnson and Sanofi-Aventis. Dr. Bishop also previously held positions at the US Food and Drug Administration (FDA) and the National Institutes of Health (NIH).
Source: Gilead Sciences
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription